Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUMMIT: Neratinib in HER mutation-positive solid tumors
NCT01953926Phase 2Terminated
- Sponsor
- Puma Biotechnology, Inc.
- Start
- Sep 2013
- Primary completion
- Jan 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 13
01
Overview
A Phase 2 trial of neratinib in solid tumor, breast cancer, Cervical Cancer (CC), non-small cell lung cancer (NSCLC), salivary gland cancer (SGC), sponsored by Puma Biotechnology, Inc.. Started Sep 2013; status: terminated.
02
Drugs
neratinib
03
Conditions
solid tumorbreast cancerCervical Cancer (CC)non-small cell lung cancer (NSCLC)salivary gland cancer (SGC)
Beyond the preview
Go deeper on NCT01953926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01953926.